How India Exports Rituximab to the World

In the United States, rituximab is approved under the brand name Rituxan for indications such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. The FDA's Orange Book lists several approved Abbreviated New Drug Applications (ANDAs) for rituximab biosimilars, reflecting a competitive market landscape. For instance, on September 27, 2019, the FDA approved Rituxan for the treatment of adult and pediatric patients aged 2 years and older with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA). This approval granted exclusivity until September 27, 2026. Given the substantial number of Indian exporters (164) and the competitive pricing, Indian manufacturers are well-positioned to meet the demand for rituximab in the U.S. market.

In the European Union, the European Medicines Agency (EMA) has authorized several rituximab biosimilars. For example, Ituxredi received marketing authorization on September 19, 2024, for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. (ema.europa.eu) However, some products have been withdrawn; Ritemvia's marketing authorization was withdrawn on June 22, 2021, at the request of the marketing authorization holder for commercial reasons. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring compliance with Good Manufacturing Practice (GMP) guidelines for manufacturing and quality control.

Rituximab is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The WHO Prequalification Programme evaluates rituximab products to ensure they meet international standards for quality, safety, and efficacy. Compliance with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) is essential for market acceptance and regulatory approval.

In India, rituximab is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing; for instance, a ceiling price was established in March 2025 to ensure affordability. Exporting rituximab requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and monitoring of export activities.

The primary patents for rituximab have expired, leading to increased generic competition and the introduction of biosimilars in various markets. This competitive environment has contributed to the diversification of suppliers and more accessible pricing, benefiting healthcare systems globally.

In June 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for Imbruvica in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma eligible for autologous stem cell transplantation. (ema.europa.eu) Additionally, in July 2023, rituximab received orphan designation from the EMA for the treatment of primary membranous nephropathy, highlighting ongoing research into new therapeutic applications. (ema.europa.eu) These developments reflect the dynamic nature of the rituximab market and the continuous efforts to expand its therapeutic indications.

India's pharmaceutical industry, including the production of Rituximab, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of APIs used in Indian pharmaceutical manufacturing are sourced from China, with KSM dependency even higher. This reliance poses significant risks, as any disruption in Chinese supply chains can directly impact India's pharmaceutical production capabilities. For instance, environmental regulations and factory shutdowns in China have previously led to shortages and price volatility in API supplies.

Recognizing this vulnerability, the Indian government has initiated measures to reduce dependence on Chinese imports. In October 2024, under the Production Linked Incentive (PLI) scheme, two greenfield plants were inaugurated to manufacture critical molecules like Penicillin G, 6-APA, and Clavulanic Acid, which are essential for antibiotic production. These efforts aim to bolster domestic API production and mitigate supply chain risks associated with external dependencies.

The export market for Rituximab from India is highly concentrated, with the top five exporters accounting for 87.1% of the total export value. Notably, DR. REDDY'S LABORATORIES LTD alone holds a 41.5% share. Such concentration poses a single-source risk; any operational disruptions within these key companies could significantly impact global supply.

To address this, the Indian government's PLI scheme aims to diversify and strengthen the pharmaceutical manufacturing base. By incentivizing the establishment of new manufacturing units and promoting the production of critical APIs domestically, the scheme seeks to reduce reliance on a limited number of suppliers and enhance supply chain resilience.

Recent geopolitical tensions have severely impacted global shipping routes critical to pharmaceutical exports. In February 2026, the Strait of Hormuz was effectively closed following military conflicts, disrupting maritime traffic in the Persian Gulf. This blockade has halted oil tanker movements and affected the distribution of pharmaceuticals from India, leading to logistical shortages and rising prices. Approximately 3,200 ships are stalled within the Persian Gulf, with 500 more waiting near UAE and Oman ports, causing worldwide supply chain disruptions.

Additionally, increased instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa’s Cape of Good Hope, adding delays and fuel surcharges. Air cargo is also under pressure due to closed airspace in several Middle Eastern countries, stranding high-value goods such as pharmaceuticals. Major cargo airlines are grounding flights or considering war risk surcharges, further complicating the logistics of pharmaceutical exports.

• Diversify API and KSM Sourcing: Invest in domestic production capabilities and explore alternative international suppliers to reduce dependency on Chinese imports.

• Expand Supplier Base: Encourage the growth of smaller pharmaceutical manufacturers to decrease market concentration and mitigate single-source risks.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify and address potential disruptions proactively.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics strategies to navigate geopolitical disruptions effectively.

• Strengthen Regulatory Compliance: Ensure adherence to international quality standards to maintain market access and consumer trust.

RISK_LEVEL: HIGH